On some "disadvantages" of the population approach
- PMID: 16353917
- PMCID: PMC2750975
- DOI: 10.1208/aapsj070238
On some "disadvantages" of the population approach
Abstract
In a seminal article on population pharmacokinetic modeling, researchers demonstrated how means and variances of pharmacokinetic parameters for a patient population could be inferred from sparse data collected under conditions of routine patient care. But they also identified 4 potential concerns about their methodology: unobserved confounding variables may bias the inferences; conditions under which data are collected may lead to inaccuracies of reporting or recording; correlations among important predictor variables may reduce statistical efficiency; and costs cannot be controlled by principles of study design. Experiences are reviewed that relate to these potential disadvantages. A method is presented for diagnosing the possible presence of confounding. A model is constructed and applied that captures the influences of data inaccuracies. An example of selecting from among correlated covariates is summarized. Finally, a methodology for optimal study design is reviewed and applied to an example.
Similar articles
-
Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments.J Biopharm Stat. 2008;18(2):342-58. doi: 10.1080/10543400701697208. J Biopharm Stat. 2008. PMID: 18327725
-
An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics.J Clin Pharmacol. 2005 Jul;45(7):832-5. doi: 10.1177/0091270005277937. J Clin Pharmacol. 2005. PMID: 15951473 Clinical Trial.
-
Quantitative assessment of unobserved confounding is mandatory in nonrandomized intervention studies.J Clin Epidemiol. 2009 Jan;62(1):22-8. doi: 10.1016/j.jclinepi.2008.02.011. Epub 2008 Jul 10. J Clin Epidemiol. 2009. PMID: 18619797 Review.
-
Population pharmacokinetics of gentamicin in horses.Am J Vet Res. 1998 Dec;59(12):1589-98. Am J Vet Res. 1998. PMID: 9858412
-
The virtual laboratory approach to pharmacokinetics: design principles and concepts.Drug Discov Today. 2006 Sep;11(17-18):800-5. doi: 10.1016/j.drudis.2006.07.001. Drug Discov Today. 2006. PMID: 16935747 Review.
Cited by
-
Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age.Antimicrob Agents Chemother. 2012 Feb;56(2):715-24. doi: 10.1128/AAC.00717-11. Epub 2011 Nov 21. Antimicrob Agents Chemother. 2012. PMID: 22106226 Free PMC article. Clinical Trial.
-
Pharmacokinetic analysis across studies to drive knowledge-integration: A tutorial on individual patient data meta-analysis (IPDMA).CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1187-1200. doi: 10.1002/psp4.13002. Epub 2023 Jun 11. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37303132 Free PMC article.
-
A Systematic Evaluation of Effect of Adherence Patterns on the Sample Size and Power of a Clinical Study.CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):818-828. doi: 10.1002/psp4.12361. Epub 2018 Oct 28. CPT Pharmacometrics Syst Pharmacol. 2018. PMID: 30291680 Free PMC article.
-
Approaches to handling missing or "problematic" pharmacology data: Pharmacokinetics.CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):291-308. doi: 10.1002/psp4.12611. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33715307 Free PMC article.
References
-
- Mentre' F, Burtin P, Merle' Y, Bree J, Mallet A, Steimer J-L. Sparse-sampling optimal designs in pharmacokinetics and toxicokinetics. Drug Inf. J. 1995;29:997–1019.
-
- Beal SL, Sheiner LB, editors. NONMEM Users Guides. Hanover, MD: GloboMax, LLC; 1989.
-
- Available at: http://www.uq.edu.au/pharmacy/sduffull/popt.htm. Accessed date: July 19, 2005.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources